Comparative study between the efficacy of prabotulinum toxin‐A versus onabotulinum toxin‐A for the treatment of upper facial expression lines

Background Botulinum Toxin (BoNTA) is the most used nonsurgical aesthetic procedure to treat facial expression lines. Aims This study compared the efficacy of Prabotulinum toxin‐A, a novel BoNTA that originates from Clostridium botulinum Hall‐A, with onabotulinum toxin‐A in treating facial expression lines using the Facial Wrinkle Scale (FWS) and FACE‐Q questionnaires. Methods This was an experimental, comparative, longitudinal, open‐label, and prospective study. Patients aged between 25 and 40 years with upper‐third facial expression lines were included. Follow‐ups were made at three, seven, 30, and 120 days. Results A total of 26 patients were included: 20 female, and six males, with a mean age of 28.26 years. An average of 31.00 IU and 31.38 IU were administered to the onabotulinum and prabotulinum groups, respectively. The prabotulinum group demonstrated superiority in FWS and Face‐Q scores between the first and third days (p ≤ 0.001, p